Search for: "Ely Lilly" Results 61 - 80 of 2,172
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Jun 2023, 1:09 pm by admin
In scientific publishing, when scientists make a mistake, they publish an erratum or a corrigendum. [read post]
10 Jun 2023, 4:02 pm by Henry P Yang
Darren Smyth (photo: Neil Graveney)The equivalents were a terrible idea, said Darren Smyth commenting on Actavis v Eli Lilly from the UK Supreme Court, which established that an infringed claim could be wider than the claim wording. [read post]
30 May 2023, 1:00 pm by Tom Lamb
It is possible that a Trulicity drug injury case could be filed against Eli Lilly, depending on the circumstances. [read post]
3 May 2023, 4:21 am
Patients who received the monthly antibody infusion during an 18-month study demonstrated a 35% slower decline in memory, thinking and their ability to perform daily activities compared to those who did not receive the treatment, Eli Lilly’s data showed. [read post]
27 Apr 2023, 9:22 am by Miquel Montañá (Clifford Chance)
In this regard, in its judgment of 12 December 2013 (case C-493/12, Eli Lilly v Human Genome Sciences), the CJEU made the following observations: “30. [read post]
3 Apr 2023, 9:05 pm by renholding
Their rank-ordered, top 20 holdings are Microsoft, Apple, Alphabet (Google), Amazon, Tesla, UnitedHealth, Nvidia, Visa, Johnson & Johnson, JPMorgan Chase, Lilly Eli, Mastercard, Facebook (now Meta), Berkshire Hathaway, ExxonMobil, Danaher, Bank of America, Thermo Fisher Scientific, Adobe Systems, and Broadcom. [read post]
8 Mar 2023, 2:51 pm by Lawrence B. Ebert
Eli Lilly & Co., 598 F.3d 1336, 1350−52 (Fed. [read post]
4 Mar 2023, 8:45 pm by Patent Docs
Irving of Finnegan Henderson Farabow Garrett & Dunner, Sarah Hooson of Merck Sharp & Dohme, Krista Kostiew of Unilever, and Xiaoguang Michelle Gao of Eli Lilly and Company will guide patent counsel on recent trends and developments in patent practice; examine the Supreme Court, Federal Circuit, and PTAB cases from the past year; and discuss some of the key developments and strategies.... [read post]
3 Mar 2023, 12:01 am by Gene Takagi
Today, Eli Lilly did that,” Biden said in a statement. [read post]
1 Mar 2023, 11:37 am by Associated Press
Eli Lilly will cut prices for some older insulins later this year and immediately give more patients access to a cap on the costs they pay to fill prescriptions. [read post]
10 Feb 2023, 4:44 am by admin
Putting aside the idiosyncratic chapter by the late Professor Berger, most of the third edition of the Reference Manual presented guidance on many important issues. [read post]
7 Feb 2023, 12:00 pm by Bernard Bell
May an agency revive a defunct rulemaking without notice, and then immediately promulgate a lightly revised version of the proposed rule as a final rule? [read post]
31 Jan 2023, 9:01 pm by renholding
For example, imagine a deepfake of Company X’s CEO promising to do something popular that would nonetheless hurt the company’s stock price—like the fake Eli Lilly tweet promising to release insulin for free. [read post]
24 Jan 2023, 7:59 pm by Kurt R. Karst
 NAD’s inquiry, brought about by a complaint from Eli Lilly (which markets a competitive drug, Verzenio (abemaciclib)), evaluated both express and implied claims made by Novartis to healthcare professionals and consumers that patients with HR+/HER2- metastatic breast cancer will live longer taking Kisqali than with other available treatments, including Verzenio. [read post]
12 Jan 2023, 4:23 pm
Aug. 31, 2016) (issuing letter of request where witness was located in Italy and possessed evidence that was relevant and unlikely to be duplicative); Eli Lilly & Co. v. [read post]
9 Jan 2023, 7:59 am by Anastasiia Kyrylenko
Upreti first discusses the role of national law in such major IP-related ISDS case, Philip Morris v Uruguay, Eli Lilly v Canada, Bridgestone v Panama, and Einarsson v Canada [also commented by The IPKat here and here]. [read post]
2 Dec 2022, 11:15 am by Steve Brachmann
Food and Drug Administration halts authorization for Eli Lilly’s COVID-19 treatment for lack of effectiveness against dominant Omicron subvariants; and more. [read post]